Taysha Gene Therapies, Inc.

TSHA Healthcare Biotechnology

Taysha Gene Therapies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.8 million, up 17.3% from fiscal 2024. In the quarter to June 2026, revenue grew 206.8%, EPS fell 44.4%, free cash flow fell 100.3% and total debt rose 20.0%, each against the same quarter a year earlier.

3.62 0.11 −2.95%
Market cap
$1.2B
P/E
0.0×
Fwd P/E
−11.5×
Dividend yield
—
F-score
4/9
Altman Z
8.05
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

— 4 — —
ROE
(64.93%) (68.45%) (97.28%) (47.05%)
ROA
(40.23%) (43.28%) (59.21%) (37.23%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(35.93%) (35.76%) (48.35%) (34.17%)
Average Days of Receivables
— 0.00 — —
Free Cash Flow per Share
(0.24) (0.29) (0.32) (0.38)
Free Cash Flow
(85.16) (93.83) (118.83) (139.07)
Other line items

Show all line items

Columns are period end dates